AIM ImmunoTech Inc’s recent filing unveils that its CEO & President Equels Thomas K acquired Company’s shares for reported $4240.0 on Nov 21 ’24. In the deal valued at $0.21 per share,20,000 shares were bought. As a result of this transaction, Equels Thomas K now holds 1,657,968 shares worth roughly $0.2 million.
Then, MITCHELL WILLIAM M sold 4,580 shares, generating $884 in total proceeds. Upon selling the shares at $0.19, the Director now owns 118,549 shares.
Before that, Equels Thomas K bought 22,727 shares. AIM ImmunoTech Inc shares valued at $4,682 were divested by the CEO & President at a price of $0.21 per share. As a result of the transaction, Equels Thomas K now holds 1,680,695 shares, worth roughly $0.2 million.
Price Performance Review of AIM
On Monday, AIM ImmunoTech Inc [AMEX:AIM] saw its stock fall -11.04% to $0.12. Over the last five days, the stock has lost -10.31%. AIM ImmunoTech Inc shares have fallen nearly -39.34% since the year began. Nevertheless, the stocks have fallen -70.05% over the past one year. While a 52-week high of $0.62 was reached on 01/07/25, a 52-week low of $0.11 was recorded on 02/25/25. SMA at 50 days reached $0.1819, while 200 days put it at $0.2797.
Levels Of Support And Resistance For AIM Stock
The 24-hour chart illustrates a support level at 0.1141, which if violated will result in even more drops to 0.1082. On the upside, there is a resistance level at 0.1320. A further resistance level may holdings at 0.1440. The Relative Strength Index (RSI) on the 14-day chart is 34.87, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0077, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.61%. Stochastics %K at 34.68% indicates the stock is a holding.
